RU2005130641A - Диагностика аутизма - Google Patents

Диагностика аутизма Download PDF

Info

Publication number
RU2005130641A
RU2005130641A RU2005130641/15A RU2005130641A RU2005130641A RU 2005130641 A RU2005130641 A RU 2005130641A RU 2005130641/15 A RU2005130641/15 A RU 2005130641/15A RU 2005130641 A RU2005130641 A RU 2005130641A RU 2005130641 A RU2005130641 A RU 2005130641A
Authority
RU
Russia
Prior art keywords
seq
autism
determined
yes
sample
Prior art date
Application number
RU2005130641/15A
Other languages
English (en)
Other versions
RU2340900C2 (ru
Inventor
Андерс ГРУББ (SE)
Андерс ГРУББ
Нагхи МОМЕНИ (SE)
Нагхи МОМЕНИ
Original Assignee
Нагхи МОМЕНИ (SE)
Нагхи МОМЕНИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нагхи МОМЕНИ (SE), Нагхи МОМЕНИ filed Critical Нагхи МОМЕНИ (SE)
Publication of RU2005130641A publication Critical patent/RU2005130641A/ru
Application granted granted Critical
Publication of RU2340900C2 publication Critical patent/RU2340900C2/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Claims (6)

1. Способ диагностики аутизма у субъектов с подозрением на аутизм посредством проведения анализа пробы ткани, пробы жидкости организма и/или пробы плазмы крови на наличие высоких концентраций определенных пептидов, имеющих молекулярную массу соответственно 1779±1 Да, 1865±1 Да и 2022±1 Да, и имеющих аминокислотные последовательности:
SKITHRIHWESASLL (SEQ. ID. № 1),
SSKITHRIHWESASLL (SEQ. ID. № 2) и/или
SSKITHRIHWESASLLR (SEQ. ID. № 3).
2. Способ по п. 1, в котором количество пептида(ов) выше в 10 раз по сравнению с таковым в пробе, полученной от субъекта без аутизма.
3. Способ по пп. 1 и 2, в котором используется любой количественный иммунохимический анализ.
4. Способ по пп. 1 и 2, в котором соответствующий пептид определяют с использованием технологии ELISA.
5. Способ по пп. 1 и 2, в котором соответствующий пептид определяют с использованием технологии РИА.
6. Способ по пп. 1 и 2, в котором соответствующий пептид определяют с использованием системы SELDI-TOF-MS.
RU2005130641/15A 2003-03-04 2004-03-02 Диагностика аутизма RU2340900C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300586A SE0300586L (sv) 2003-03-04 2003-03-04 Diagnos av autism
SE0300586-5 2003-03-04

Publications (2)

Publication Number Publication Date
RU2005130641A true RU2005130641A (ru) 2006-02-10
RU2340900C2 RU2340900C2 (ru) 2008-12-10

Family

ID=20290572

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005130641/15A RU2340900C2 (ru) 2003-03-04 2004-03-02 Диагностика аутизма

Country Status (19)

Country Link
US (1) US8268576B2 (ru)
EP (1) EP1608982B9 (ru)
JP (1) JP4452715B2 (ru)
KR (1) KR101096487B1 (ru)
CN (1) CN1795386B (ru)
AT (1) ATE371192T1 (ru)
AU (1) AU2004217571B2 (ru)
BR (1) BRPI0408067A (ru)
CA (1) CA2518066C (ru)
DE (1) DE602004008439T2 (ru)
DK (1) DK1608982T3 (ru)
ES (1) ES2293234T3 (ru)
NZ (1) NZ542149A (ru)
PL (1) PL1608982T3 (ru)
PT (1) PT1608982E (ru)
RU (1) RU2340900C2 (ru)
SE (1) SE0300586L (ru)
WO (1) WO2004079371A1 (ru)
ZA (1) ZA200507082B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4677556B2 (ja) * 2005-04-22 2011-04-27 国立大学法人 千葉大学 自閉症の診断薬
SG182971A1 (en) * 2007-07-26 2012-08-30 Phenomenome Discoveries Inc Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
CA2821908C (en) * 2010-12-16 2018-09-18 Autism Biotech Limited Novel biomarker and uses thereof in diagnosis, treatment of autism
WO2014018468A1 (en) 2012-07-22 2014-01-30 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
PL3058371T3 (pl) 2013-10-14 2021-11-08 Indiana University Research And Technology Corporation Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
US11131681B2 (en) * 2017-03-10 2021-09-28 Dr. Raymond Laboratories, Inc. Method for diagnosing psychiatric disorders
WO2018164536A1 (ko) 2017-03-10 2018-09-13 스핑고브레인 주식회사 정신장애의 진단 방법
RU2643760C1 (ru) * 2017-08-07 2018-02-05 Федеральное государственное бюджетное научное учреждение "Научный центр психического здоровья" Способ определения необходимости использования психофармакотерапии у пациентов с расстройствами аутистического спектра на момент их обследования
KR20190106442A (ko) 2018-03-09 2019-09-18 스핑고브레인 주식회사 태지, 양수 또는 제대혈을 이용한 정신장애의 진단 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
IT1303675B1 (it) * 1998-08-04 2001-02-23 Radim S P A Metodo di determinazione di peptidi utilizzati come marker per ladiagnosi dell'autismo
CA2387801A1 (en) 1999-11-04 2001-05-10 Human Genome Sciences, Inc. Uteroglobin-like polynucleotides, polypeptides, and antibodies
US6998243B2 (en) 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons

Also Published As

Publication number Publication date
EP1608982B9 (en) 2008-07-23
EP1608982B1 (en) 2007-08-22
PL1608982T3 (pl) 2008-01-31
PT1608982E (pt) 2007-11-09
RU2340900C2 (ru) 2008-12-10
AU2004217571B2 (en) 2009-03-12
KR20060006774A (ko) 2006-01-19
ES2293234T3 (es) 2008-03-16
CA2518066C (en) 2011-05-10
US8268576B2 (en) 2012-09-18
ATE371192T1 (de) 2007-09-15
CN1795386A (zh) 2006-06-28
DK1608982T3 (da) 2007-11-26
US20120149038A1 (en) 2012-06-14
ZA200507082B (en) 2007-02-28
CN1795386B (zh) 2010-08-25
DE602004008439T2 (de) 2008-05-21
CA2518066A1 (en) 2004-09-16
KR101096487B1 (ko) 2011-12-20
WO2004079371A1 (en) 2004-09-16
JP2006519391A (ja) 2006-08-24
JP4452715B2 (ja) 2010-04-21
EP1608982A1 (en) 2005-12-28
SE0300586L (sv) 2004-09-05
AU2004217571A1 (en) 2004-09-16
SE0300586D0 (sv) 2003-03-04
NZ542149A (en) 2008-03-28
DE602004008439D1 (de) 2007-10-04
BRPI0408067A (pt) 2006-02-14

Similar Documents

Publication Publication Date Title
US8268576B2 (en) Diagnosis of autism
Perry et al. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid
RU2010135526A (ru) Новый способ количественного определения и охарактеризования микровезикул в жидкостях организма человека
JP2011510309A5 (ru)
RU2014123987A (ru) Анализ адромедуллина и способы определения зрелого адромедуллина
RU2012120706A (ru) Диагностические и терапевтические способы
RU2015116674A (ru) Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
CN108398503A (zh) 一种乳铁蛋白的液相色谱质谱检测方法
US20110160434A1 (en) Fibromyalgia test method
US8420331B2 (en) Type IV collagen-like immunoreactive peptide
RU2014102721A (ru) Способ получения агента, связывающегося с препро-вазопрессином или с его фрагментами
US10175250B2 (en) Nitrated cardiac troponin I as a biomarker of cardiac ischemia
JP2009244225A (ja) 脳炎の診断方法及び脳炎の診断システム
TWI606060B (zh) 用於檢測神經性乙醯膽鹼受器阿爾法七次單位抗體之多肽分子
JP2024029191A (ja) 認知症又はそのリスクの検査方法
CN111537749A (zh) Myh9在制备重度少弱精症诊断试剂中的应用
JP2020064051A (ja) 神経変性疾患の診断用ペプチドマーカー

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130303